Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Yatsen Holding (YSG) Reports Q2 Loss of $0.16
• GitLab Inc (GTLB) PT Raised to $55 at Rosenblatt, 'We remain buyers of the stock'
• Kontoor Brands sets Helly Hansen revenue target above $1.1B by 2030